On demand prostacyclin inhalation in obstructive pulmonary disease and pulmonary hypertension

ISRCTN ISRCTN61661881
DOI https://doi.org/10.1186/ISRCTN61661881
Secondary identifying numbers 1.2
Submission date
06/10/2009
Registration date
11/11/2009
Last edited
25/02/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr Daiana Stolz
Scientific

Petersgraben 4
Basel
4031
Switzerland

Email stolzd@uhbs.ch

Study information

Study designInvestigator driven single centre prospective randomised double-blind crossover study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleOn demand prostacyclin inhalation in obstructive pulmonary disease and pulmonary hypertension: a single centre prospective randomised double-blind crossover study
Study acronymThe OPTION pilot study
Study hypothesisWe hypothesise that inhalative iloprost improves the exercise capacity in chronic obstructive pulmonary disease (COPD) patients with secondary pulmonary hypertension (PH).
Ethics approval(s)Ethics Committee of Basel (Ethikkommission Beider Basel, Switzerland) approved on the 10th August 2009 (ref: EKBB 190/09)
ConditionChronic obstructive pulmonary disease (COPD) with secondary pulmonary hypertension
InterventionIn every of the three study visits the patient will inhale one of the following in a randomised manner prior to the exercise test:
1. 0.9% saline (2 ml)
2. 10 μg iloprost diluted in 0.9% saline (2 ml)
3. 20 μg iloprost diluted in 0.9% saline (2 ml)

All study visits have to be done on different days within one month.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Iloprost
Primary outcome measureSix-minute walking distance (6MWD) test, measured during the three study visits, after every inhalation.
Secondary outcome measuresMeasured during the three study visits, after every inhalation:
1. Oxygen consumption
2. Oxygen saturation
3. Ventilation
4. Carbon dioxide production
5. Arterial oxygen content
6. Alveolar-arterial gradient
7. BORG score
Overall study start date01/10/2009
Overall study end date01/11/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants17
Participant inclusion criteria1. Patients with diagnosed COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] I - IV)
2. Confirmed disproportional pulmonary arterial hypertension (mean pulmonary artery pressure of over 45 mmHg during exercise and/or over 30 mmHg at rest)
3. Aged above 40 years, men and women
Participant exclusion criteria1. Mental disorder preventing appropriate judgment concerning study participation
2. Significant comorbidity resulting in reduced life expectancy (lower than 6 months)
3. Significant exacerbation of COPD within the last month
4. Decompensated heart failure (left ventricular ejection fraction below 30%)
5. Present pulmonary embolism
6. PH explained by another cause than COPD
7. Pregnant and breastfeeding women
Recruitment start date01/10/2009
Recruitment end date01/11/2010

Locations

Countries of recruitment

  • Switzerland

Study participating centre

Petersgraben 4
Basel
4031
Switzerland

Sponsor information

University Hospital Basel (Switzerland)
Hospital/treatment centre

Petersgraben 4
Basel
4031
Switzerland

Website http://www.unispital-basel.ch/
ROR logo "ROR" https://ror.org/04k51q396

Funders

Funder type

Hospital/treatment centre

University Hospital Basel (Switzerland)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/04/2012 Yes No